TDC
BCLI

Thompson Davis & Co’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Thompson Davis & Co’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-13
Closed -$1K – 711
2018
Q2 		$1K Buy
+13
New +$765 ﹤0.01% 638
2017
Q2 		– Sell
-100
Closed -$6K – 1082
2017
Q1 		$6K Buy
+100
New +$5.2K 0.01% 838

Other funds holding BCLI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CPP
Crow Point Partners Boston, Massachusetts $64M AUM 33.5% 1-Year Est. Return

Thompson Davis & Co's BCLI Position: Q3 2018 in Review

Thompson Davis & Co sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2018, closing a stake of 13 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in BCLI in Q1 2017 and held it in 2 quarters. The position peaked at $6K in Q1 2017. 37 funds tracked by Wall St. Rank hold BCLI as of Q3 2018.

  • Thompson Davis & Co reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 13 BRAINSTORM CELL THERAPUTC shares in Q3 2018, an estimated $1K.
  • Thompson Davis & Co first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2017 and held it in 2 quarters.
  • Thompson Davis & Co's BRAINSTORM CELL THERAPUTC position peaked at $6K in Q1 2017.
  • 37 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.